According to a research team at the Duke University Medical Center Preston Robert Tisch Brain Tumor Center, a low dosage of a modified poliovirus therapy shows promising results for patients with a glioblastoma, or GBM, a highly malignant brain tumor.
Study findings of the first 20 patients in the Phase I trial were presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
“For chemotherapy, we are trained to give the largest dose possible with acceptable toxicity, because that is how the drugs work to attack tumors,” said lead author, Annick Desjardins, M.D., director of clinical research at the brain tumor center in the Duke Cancer Institute. "But that does not appear to be necessary with our therapy, and in fact a lower dose attacks the tumor as well and results in fewer side effects."
Read more about this study online.